Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Altay Therapeutics closed a $37 million Series A financing co-led by Sound Bioventures and HealthCap. The biotechnology company develops small-molecule inhibitors of transcription factors. Proceeds will advance oral DUX4 inhibitor DX5057 through Phase 1 and Phase 2 proof-of-concept trials for facioscapulohumeral muscul
Altay Therapeutics closed a $37 million Series A financing with participation from Fountain Healthcare Partners. Sound Bioventures and HealthCap co-led the round. * Altay develops small-molecule inhibitors of transcription factors; its lead candidate, oral DUX4 inhibitor DX5057, targets facioscapulohumeral muscular dys